High throughput genetic analysis of congenital myasthenic syndromes using resequencing microarrays

Lisa Denning, Jennifer A. Anderson, Ryan Davis, Jeffrey Gregg, Jennifer Kuzdenyi, Ricardo A Maselli

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background. The use of resequencing microarrays for screening multiple, candidate disease loci is a promising alternative to conventional capillary sequencing. We describe the performance of a custom resequencing microarray for mutational analysis of Congenital Myasthenic Syndromes (CMSs), a group of disorders in which the, normal process of neurnmuscular transmission is impaired. Methodology/Principal Findings. Our microarray was designed to assay the exons and flanking intronic regions of 8 genes linked to CMSs. A total of 31 microarrays were hybridized with genomic DNA from either individuals with known CMS mutations or from healthy controls. We estimated an overall microarray call rate of 93.61%, and we found the percentage agreement between the microarray and capillary sequencing techniques to be 99.95%. In addition, our microarray exhibited 100% specificity and 99.99% reproducibility. Finally, the microarray detected 22 out of the 23 known missense mutations, but it failed to detect all 7 known insertion and deletion (indels) mutations, indicating an overall sensitivity of 73.33% and a sensitivity with respect to missense mutations of 95.65%. Conclusions/Significance. Overall, our microarray prototype exhibited strong performance and proved highly efficient for screening genes associated with CMSs. Until indels can be efficiently assayed with this technology, however, we recommend using resequencing microarrays for screening CMS mutations after common indels have been first assayed by capillary sequencing.

Original languageEnglish (US)
Article numbere918
JournalPLoS One
Volume2
Issue number9
DOIs
StatePublished - Sep 19 2007

Fingerprint

Congenital Myasthenic Syndromes
Microarrays
genetic techniques and protocols
missense mutation
Throughput
screening
mutation
Missense Mutation
prototypes
reproducibility
exons
INDEL Mutation
genes
Screening
Mutation
genomics
Microarray Analysis
loci
Genes
DNA

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

High throughput genetic analysis of congenital myasthenic syndromes using resequencing microarrays. / Denning, Lisa; Anderson, Jennifer A.; Davis, Ryan; Gregg, Jeffrey; Kuzdenyi, Jennifer; Maselli, Ricardo A.

In: PLoS One, Vol. 2, No. 9, e918, 19.09.2007.

Research output: Contribution to journalArticle

Denning, Lisa ; Anderson, Jennifer A. ; Davis, Ryan ; Gregg, Jeffrey ; Kuzdenyi, Jennifer ; Maselli, Ricardo A. / High throughput genetic analysis of congenital myasthenic syndromes using resequencing microarrays. In: PLoS One. 2007 ; Vol. 2, No. 9.
@article{db6925a92f784197bcc8f0f6ee07e83d,
title = "High throughput genetic analysis of congenital myasthenic syndromes using resequencing microarrays",
abstract = "Background. The use of resequencing microarrays for screening multiple, candidate disease loci is a promising alternative to conventional capillary sequencing. We describe the performance of a custom resequencing microarray for mutational analysis of Congenital Myasthenic Syndromes (CMSs), a group of disorders in which the, normal process of neurnmuscular transmission is impaired. Methodology/Principal Findings. Our microarray was designed to assay the exons and flanking intronic regions of 8 genes linked to CMSs. A total of 31 microarrays were hybridized with genomic DNA from either individuals with known CMS mutations or from healthy controls. We estimated an overall microarray call rate of 93.61{\%}, and we found the percentage agreement between the microarray and capillary sequencing techniques to be 99.95{\%}. In addition, our microarray exhibited 100{\%} specificity and 99.99{\%} reproducibility. Finally, the microarray detected 22 out of the 23 known missense mutations, but it failed to detect all 7 known insertion and deletion (indels) mutations, indicating an overall sensitivity of 73.33{\%} and a sensitivity with respect to missense mutations of 95.65{\%}. Conclusions/Significance. Overall, our microarray prototype exhibited strong performance and proved highly efficient for screening genes associated with CMSs. Until indels can be efficiently assayed with this technology, however, we recommend using resequencing microarrays for screening CMS mutations after common indels have been first assayed by capillary sequencing.",
author = "Lisa Denning and Anderson, {Jennifer A.} and Ryan Davis and Jeffrey Gregg and Jennifer Kuzdenyi and Maselli, {Ricardo A}",
year = "2007",
month = "9",
day = "19",
doi = "10.1371/journal.pone.0000918",
language = "English (US)",
volume = "2",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

TY - JOUR

T1 - High throughput genetic analysis of congenital myasthenic syndromes using resequencing microarrays

AU - Denning, Lisa

AU - Anderson, Jennifer A.

AU - Davis, Ryan

AU - Gregg, Jeffrey

AU - Kuzdenyi, Jennifer

AU - Maselli, Ricardo A

PY - 2007/9/19

Y1 - 2007/9/19

N2 - Background. The use of resequencing microarrays for screening multiple, candidate disease loci is a promising alternative to conventional capillary sequencing. We describe the performance of a custom resequencing microarray for mutational analysis of Congenital Myasthenic Syndromes (CMSs), a group of disorders in which the, normal process of neurnmuscular transmission is impaired. Methodology/Principal Findings. Our microarray was designed to assay the exons and flanking intronic regions of 8 genes linked to CMSs. A total of 31 microarrays were hybridized with genomic DNA from either individuals with known CMS mutations or from healthy controls. We estimated an overall microarray call rate of 93.61%, and we found the percentage agreement between the microarray and capillary sequencing techniques to be 99.95%. In addition, our microarray exhibited 100% specificity and 99.99% reproducibility. Finally, the microarray detected 22 out of the 23 known missense mutations, but it failed to detect all 7 known insertion and deletion (indels) mutations, indicating an overall sensitivity of 73.33% and a sensitivity with respect to missense mutations of 95.65%. Conclusions/Significance. Overall, our microarray prototype exhibited strong performance and proved highly efficient for screening genes associated with CMSs. Until indels can be efficiently assayed with this technology, however, we recommend using resequencing microarrays for screening CMS mutations after common indels have been first assayed by capillary sequencing.

AB - Background. The use of resequencing microarrays for screening multiple, candidate disease loci is a promising alternative to conventional capillary sequencing. We describe the performance of a custom resequencing microarray for mutational analysis of Congenital Myasthenic Syndromes (CMSs), a group of disorders in which the, normal process of neurnmuscular transmission is impaired. Methodology/Principal Findings. Our microarray was designed to assay the exons and flanking intronic regions of 8 genes linked to CMSs. A total of 31 microarrays were hybridized with genomic DNA from either individuals with known CMS mutations or from healthy controls. We estimated an overall microarray call rate of 93.61%, and we found the percentage agreement between the microarray and capillary sequencing techniques to be 99.95%. In addition, our microarray exhibited 100% specificity and 99.99% reproducibility. Finally, the microarray detected 22 out of the 23 known missense mutations, but it failed to detect all 7 known insertion and deletion (indels) mutations, indicating an overall sensitivity of 73.33% and a sensitivity with respect to missense mutations of 95.65%. Conclusions/Significance. Overall, our microarray prototype exhibited strong performance and proved highly efficient for screening genes associated with CMSs. Until indels can be efficiently assayed with this technology, however, we recommend using resequencing microarrays for screening CMS mutations after common indels have been first assayed by capillary sequencing.

UR - http://www.scopus.com/inward/record.url?scp=41249100617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41249100617&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0000918

DO - 10.1371/journal.pone.0000918

M3 - Article

C2 - 17878953

AN - SCOPUS:41249100617

VL - 2

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - e918

ER -